Search for: "Johnson v. Lilly"
Results 41 - 60
of 125
Sorted by Relevance
|
Sort by Date
1 Jun 2017, 9:45 am
Forsythe, Clarke D., Abuse of Discretion: The Inside Story of Roe v. [read post]
5 May 2021, 4:59 am
How Not to Read the Eli Lilly vs Canada Award” Commentator: Rochelle Dreyfuss 12:10 PM ET Christopher S. [read post]
29 May 2014, 5:00 am
April 11, 2002); Lillie v. [read post]
13 Jun 2011, 7:54 am
Intel Corp., Eli Lilly & Co., Johnson & Johnson, and Pfizer Inc. were among the companies that supported Roche. [read post]
3 Dec 2009, 12:13 am
They've cited, most recently, the Court's 5-4 decision this year in Ashcroft v. [read post]
10 Jun 2011, 4:09 pm
Cir. 1997) (hereinafter, Eli Lilly). [read post]
5 Jun 2007, 10:16 am
The legislative debate follows the Supreme Court’s ruling last month in KSR v. [read post]
3 Mar 2016, 5:19 am
Johnson & Johnson Corp. v. [read post]
17 Jun 2009, 3:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: Gene patenting debate continues: UCLA v USPTO (Patent Docs) (Patent Docs) (PatentlyBIOtech) (Patent Docs) (IP Watchdog) US: FTC issues highly anticipated report on follow-on biologics; report concludes that special legislative exclusivity incentives are largely unwarranted for innovators and generics (FDA Law Blog) (Patent Docs)… [read post]
17 Jun 2009, 3:02 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: US: Gene patenting debate continues: UCLA v USPTO (Patent Docs) (Patent Docs) (PatentlyBIOtech) (Patent Docs) (IP Watchdog) US: FTC issues highly anticipated report on follow-on biologics; report concludes that special legislative exclusivity incentives are largely unwarranted for innovators and generics (FDA Law Blog) (Patent Docs) (Patent… [read post]
18 Jul 2014, 11:55 am
Wyeth, Inc., ___ N.W.2d ___, 2014 WL 3377071 (Iowa July 11, 2014), but Huck isn’t even the last case on our scorecard any longer – that honor currently belongs to Johnson v. [read post]
1 May 2009, 9:00 am
(IAM) US: Johnson & Johnson – 5 year exclusivity period would kill incentives to innovate (Patent Docs) US: CHI CEO on patent reform and follow-on biologics legislation (Patent Docs) US: BIO urges Congress on patent reform: First, do no harm (Patent Baristas) US: Pharmaceutical advertising: How to use a domain name to circumvent application of law (Domain Name / Nom De Domaine!) [read post]
9 May 2012, 11:09 am
Johnson & Johnson and Baum v. [read post]
11 Dec 2019, 2:00 am
For example, an Alabama federal district court judge relied on the 2009 regulations as a basis for his recent ruling that an employer cannot deny FMLA leave based on FMLA-specific callout requirements that exceed what the employer requires for other types of leave. #3 Lilly Ledbetter Fair Pay Act: The signing of the Lilly Ledbetter Act in February 2009—reversing the Supreme Court decision Ledbetter v. [read post]
21 Jun 2012, 4:30 am
Johnson & Johnson Corp. v. [read post]
8 Oct 2015, 5:00 am
Eli Lilly & Co., 58 F. [read post]
22 Mar 2007, 5:34 am
Feb. 28, 1996); Johnson v. [read post]
2 May 2009, 10:12 am
LILLI M. [read post]
25 May 2011, 8:52 pm
From the pharmaceutical industry, amicus briefs were filed by Apotex; Sanofi-Aventis; Eli Lilly & Co.; BIO; Eisai; Johnson & Johnson; PhRMA; Teva; and GPhA. [read post]
19 Apr 2016, 3:27 am
Empirical SCOTUS; Kevin Johnson, who at Immigration Prof Blog concludes that “the Obama administration may come out okay in United States v. [read post]
